Dostarlimab shows preliminary but durable activity across multiple cancers
Promising data are reported for tumours with dMMR, MSI-H and rare POLE alterations, reinforcing the role of molecular testing for tissue-agnostic treatment
Promising data are reported for tumours with dMMR, MSI-H and rare POLE alterations, reinforcing the role of molecular testing for tissue-agnostic treatment
Negative results from the ASCOT trial should not discourage researchers from investigating the drug’s potential in some molecularly distinct subgroups
Despite positive results from trials, the use of different assays with variable sensitivities and specificities impact their interpretation and clinical validation
In the NICHE-3 study, all patients achieved a pathological response
Results presented at ESMO Congress 2023 open-up an interesting debate on the use of currently recommended treatment regimens
Results from the JCOG1611-GENERATE trial fuel the debate around the preferred option in this setting
Neoadjuvant, perioperative, targeted and combined treatment approaches have shown potential benefit for patients with this aggressive disease, but further research is needed
In the DESTINY-PanTumour01 trial, promising response rates were seen with trastuzumab deruxtecan in heavily pre-treated patients with different cancer types
Adding immunotherapy to standard of care shows benefit compared with placebo and is confirmed to be practice-changing for this patient population
The impact of immunotherapy on disease progression and survival remains uncertain, but biomarker selection may be the future
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.